Literature DB >> 15266769

Preemptive meloxicam for postoperative pain relief after abdominal hysterectomy.

T Akarsu1, S Karaman, F Akercan, M Kazandi, M S Yucebilgin, V Firat.   

Abstract

OBJECTIVE: This study was conducted to evaluate the analgesic efficacy of meloxicam in abdominal hysterectomy.
METHODS: The study population consisted of 52 patients scheduled for total abdominal hysterectomy who were ASA 1 or 2 physical status female. Patients were allocated randomly to receive orally either 15 mg of meloxicam (Group M, n = 27) or placebo (Group P, n = 25) before anesthesia induction. After intravenous administration of 1.5 mg kg(-1) of tramadol, anesthesia was induced with an intravenous loading dose of 1-2 mg kg(-1) propofol. Anesthesia was maintained on intravenous infusion of propofol at 6-12 mg kg(-1) h plus tramadol at 1 mg kg(-1) h(-1), vecuronium, and a 2:1 nitrous oxide-oxygen mixture.
RESULTS: The relative propofol consumption was lower in Group M than in Group P, (p < 0.05). The time for analgesic rescue decreased in the order Group M > Group P (p < 0.01). The degree of sedation was similar between the groups (p > 0.05) and the visual analog scores (10-cm scale) and verbal rating scale data differences were present in the first 2 h only (p < 0.05). When side-effects were evaluated nausea and vomiting were found to be lower in group M than in group P (p < 0.05).
CONCLUSION: Preemptive meloxicam provided better postoperative analgesia than placebo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15266769

Source DB:  PubMed          Journal:  Clin Exp Obstet Gynecol        ISSN: 0390-6663            Impact factor:   0.146


  1 in total

1.  Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial.

Authors:  Tomasz Rechberger; Randall J Mack; Stewart W McCallum; Wei Du; Alex Freyer
Journal:  Anesth Analg       Date:  2019-06       Impact factor: 5.108

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.